JP2014530001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530001A5 JP2014530001A5 JP2014531755A JP2014531755A JP2014530001A5 JP 2014530001 A5 JP2014530001 A5 JP 2014530001A5 JP 2014531755 A JP2014531755 A JP 2014531755A JP 2014531755 A JP2014531755 A JP 2014531755A JP 2014530001 A5 JP2014530001 A5 JP 2014530001A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- tnf
- light chain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 37
- 229920001184 polypeptide Polymers 0.000 claims 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims 35
- 102100027211 Albumin Human genes 0.000 claims 28
- 108010088751 Albumins Proteins 0.000 claims 28
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 24
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 24
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 16
- 238000006467 substitution reaction Methods 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 6
- 230000004927 fusion Effects 0.000 claims 6
- 102220563880 Glucagon receptor_V15P_mutation Human genes 0.000 claims 4
- 241000283984 Rodentia Species 0.000 claims 4
- 102220359436 c.238T>A Human genes 0.000 claims 4
- 102200074797 rs111033564 Human genes 0.000 claims 4
- 102200150982 rs28939717 Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000000539 dimer Substances 0.000 claims 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 claims 2
- 102220536557 Transcription factor NF-E4_A45D_mutation Human genes 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 102000057041 human TNF Human genes 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 102200082944 rs1135071 Human genes 0.000 claims 2
- 102220075538 rs796053378 Human genes 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161538548P | 2011-09-23 | 2011-09-23 | |
| US61/538,548 | 2011-09-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530001A JP2014530001A (ja) | 2014-11-17 |
| JP2014530001A5 true JP2014530001A5 (enExample) | 2015-11-12 |
Family
ID=47146619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014531755A Pending JP2014530001A (ja) | 2011-09-23 | 2012-09-19 | 抗腫瘍壊死因子−α剤及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9399678B2 (enExample) |
| EP (1) | EP2758434A2 (enExample) |
| JP (1) | JP2014530001A (enExample) |
| CN (1) | CN103906765A (enExample) |
| AU (1) | AU2012310328A1 (enExample) |
| BR (1) | BR112014006929A2 (enExample) |
| CA (1) | CA2849409A1 (enExample) |
| SG (2) | SG10201504605RA (enExample) |
| WO (1) | WO2013043070A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201504605RA (en) * | 2011-09-23 | 2015-07-30 | Technophage Investigação E Desenvolvimento Em Biotecnologia Sa | Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| DE102014112212A1 (de) * | 2014-08-26 | 2016-03-03 | Akesion Gmbh | Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen |
| US20180071367A1 (en) * | 2015-03-09 | 2018-03-15 | Oxeia Biopharmaceuticals, Inc. | Methods of treating cognitive impairments or dysfunction |
| CN113912717B (zh) * | 2016-02-05 | 2024-05-03 | 得克萨斯大学体系董事会 | Egfl6特异性单克隆抗体及其使用方法 |
| US20200033363A1 (en) * | 2017-03-27 | 2020-01-30 | Garvan Institute Of Medical Research | Screening methods |
| WO2019032827A1 (en) | 2017-08-09 | 2019-02-14 | Massachusetts Institute Of Technology | PEPTIDE ALBUMIN BINDING CONJUGATES AND METHODS THEREOF |
| CN110066337B (zh) * | 2019-05-16 | 2022-06-21 | 艾柏森(江苏)生物科技有限公司 | 一种抗TNF-α抗体 |
| US11224858B1 (en) | 2020-10-01 | 2022-01-18 | Immunicom, Inc. | Reduced leaching of a ligand |
| KR20230074799A (ko) * | 2020-10-01 | 2023-05-31 | 이뮤니컴 인코포레이티드 | 리간드의 침출 감소 |
| CN118930648B (zh) * | 2024-08-22 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人pax8蛋白的兔单克隆抗体、抗体偶联物及其应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1991006287A1 (en) | 1989-11-06 | 1991-05-16 | Enzytech, Inc. | Protein microspheres and methods of using them |
| SE9002213D0 (sv) | 1990-06-21 | 1990-06-21 | Hightech Receptor Ab | Albumin binding proteins |
| FI85768C (fi) | 1990-07-04 | 1992-05-25 | Valtion Teknillinen | Foerfarande foer utfoerning av ytplasmonresonansmaetning samt i foerfarandet anvaendbar givare. |
| DE69110032T2 (de) | 1991-06-08 | 1995-12-21 | Hewlett Packard Gmbh | Verfahren und Gerät zur Feststellung und/oder Konzentrationsbestimmung von Biomolekülen. |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5643570A (en) | 1992-05-19 | 1997-07-01 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
| US6962686B2 (en) | 1994-10-12 | 2005-11-08 | California Institute Of Technology | Cell-specific gene delivery vehicles |
| WO1996020698A2 (en) | 1995-01-05 | 1996-07-11 | The Board Of Regents Acting For And On Behalf Of The University Of Michigan | Surface-modified nanoparticles and method of making and using same |
| WO1997007788A2 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| GB9623820D0 (en) | 1996-11-16 | 1997-01-08 | Secr Defence | Surface plasma resonance sensor |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| GB2339430A (en) * | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| CA2319429A1 (en) | 1998-05-20 | 1999-11-25 | Graffinity Pharmaceutical Design Gmbh | Surface plasmon resonance sensor for the simultaneous measurement of a plurality of samples in fluid form |
| US6289286B1 (en) | 1998-05-29 | 2001-09-11 | Biacore Ab | Surface regeneration of biosensors and characterization of biomolecules associated therewith |
| US6311415B1 (en) | 1998-09-14 | 2001-11-06 | Lind Shoe Company | Bowling shoe with replaceable tip |
| US6319691B1 (en) | 1999-06-15 | 2001-11-20 | Usa Universe Bioengineering, Inc. | Fusion proteins comprising IFN-alpha2b and TM-alpha1 |
| US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| AU784285B2 (en) | 1999-12-24 | 2006-03-02 | Genentech Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| CA2492092A1 (en) * | 2002-06-28 | 2004-01-08 | Greg Winter | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| JP5634008B2 (ja) | 2004-04-06 | 2014-12-03 | アフィボディ・アーベー | 新規の使用および方法 |
| BR122013001996B1 (pt) | 2005-05-18 | 2022-02-01 | Ablynx N.V. | Nanocorpos melhorados contra fator alfa de necrose tumoral |
| EA017417B1 (ru) | 2006-02-01 | 2012-12-28 | Сефалон Астралия Пти Лтд. | КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ |
| CA2733742A1 (en) | 2008-08-14 | 2010-02-18 | Cephalon Australia Pty Ltd | Variant domain antibodies |
| BR122018013284B1 (pt) | 2008-10-29 | 2022-03-03 | Ablynx N.V | Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab |
| US20110195395A1 (en) | 2010-02-10 | 2011-08-11 | Selinfreund Richard H | Rinse composition for the stabilization of diagnostic biomarkers |
| MX361242B (es) * | 2011-03-30 | 2018-11-30 | Ablynx Nv | Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos. |
| SG10201504605RA (en) * | 2011-09-23 | 2015-07-30 | Technophage Investigação E Desenvolvimento Em Biotecnologia Sa | Anti-Tumor Necrosis Factor-Alpha Agents And Uses Thereof |
-
2012
- 2012-09-19 SG SG10201504605RA patent/SG10201504605RA/en unknown
- 2012-09-19 CA CA2849409A patent/CA2849409A1/en not_active Abandoned
- 2012-09-19 US US14/346,151 patent/US9399678B2/en not_active Expired - Fee Related
- 2012-09-19 JP JP2014531755A patent/JP2014530001A/ja active Pending
- 2012-09-19 CN CN201280053629.1A patent/CN103906765A/zh active Pending
- 2012-09-19 WO PCT/PT2012/000035 patent/WO2013043070A2/en not_active Ceased
- 2012-09-19 BR BR112014006929A patent/BR112014006929A2/pt active Search and Examination
- 2012-09-19 AU AU2012310328A patent/AU2012310328A1/en not_active Abandoned
- 2012-09-19 SG SG11201400879SA patent/SG11201400879SA/en unknown
- 2012-09-19 EP EP12783676.5A patent/EP2758434A2/en not_active Ceased
-
2016
- 2016-07-22 US US15/217,495 patent/US20170137510A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530001A5 (enExample) | ||
| US20240392002A1 (en) | Anti-ror antibody constructs | |
| KR102482710B1 (ko) | 항-pd-1 항체, 이의 생산 방법 및 사용 방법 | |
| JP7373650B2 (ja) | 抗pd-l1シングルドメイン抗体 | |
| JP2013523184A5 (enExample) | ||
| JP2010535012A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| IL280467B1 (en) | Antibody constructs for cldn18.2 and cd3 | |
| JP2019522490A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2018502050A5 (enExample) | ||
| JP2012515540A5 (enExample) | ||
| JP2016507523A5 (enExample) | ||
| JP2018527908A (ja) | Dll3及びcd3に結合する二重特異性抗体構築物 | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2018503380A5 (enExample) | ||
| JP2012518425A5 (enExample) | ||
| JP2010533498A5 (enExample) | ||
| AU2015328090A1 (en) | Humanized anti-OX40 antibodies and uses thereof | |
| JP2014503189A5 (enExample) | ||
| TW201716441A (zh) | Egfrviii及cd3抗體構築體 | |
| JP2012525829A5 (enExample) | ||
| RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека | |
| JP2014524733A5 (enExample) | ||
| JP2018510617A5 (enExample) |